PTEN dosage is essential for neurofibroma development and malignant transformation
Caroline Gregorian(Institute for Molecular Medicine), Hong Wu(University of Alberta), Ingo K. Mellinghoff(Memorial Sloan Kettering Cancer Center), Kate Barzan Smith(University of California, Los Angeles), Phioanh L. Nghiemphu(Los Angeles Medical Center), Paul S. Mischel(University of California, Los Angeles), Julie Dang(Centre National de la Recherche Scientifique), Gregory Lawson(University of California, Los Angeles), Sarah Dry, Fritz C. Eilber(APLA Health), Xin Liu(University of California, Los Angeles), Michael E. Phelps(National Academy of Engineering), Jonathan Nakashima(University of California, Los Angeles), Luis F. Parada(Memorial Sloan Kettering Cancer Center), Yan Ao(University of California, Los Angeles), Michael V. Sofroniew(University of California, Los Angeles)
Cited by 118
Related Papers
Astrocytes: biology and pathology
|Acta Neuropathologica|2009|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Quantitation in Positron Emission Computed Tomography
|Journal of Computer Assisted Tomography|1979|1.2k